Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The New Era in DTC: FDA Plans New Fees, Fines-and Creative Advice

This article was originally published in RPM Report

Executive Summary

The new FDA law marks a turning point in the relatively short history of direct-to-consumer broadcast ads. Sponsors have preserved the right to advertise, but will have to get used to following FDA's schedule-and taking FDA's advice.

Related Content

"Neutral" Is "Unbiased" In FDA' s Lexicon: Taking the Buzz and Distractions Out of Risk Statements
DTC User Fees Shot Down; Advertisers Face More Perilous Future
Clarifying "Clear, Conspicuous and Neutral": Advertisers Will Learn New DTC Standard on the Fly
Pyramid Schemes and Pipeline Dreams: Adapting to a Tiered Regulatory System for New Drugs
Nickel and Diming FDA
FDA Amendments Act: More Regulation = More Comfort and More Products
Go Ahead and Advertise--If You Dare
Go Ahead and Advertise--If You Dare
The New Economics of DTC: Responsibility Sells
FDA's Consumer Ad Watchdogs


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts